Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma

BACKGROUND: Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in head and neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into the clinical management of HNSCC has not led to significant changes in long-term survival outcomes....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Espinosa-Cotton, Madelyn, Rodman III, Samuel N., Ross, Kathleen A., Jensen, Isaac J., Sangodeyi-Miller, Kenley, McLaren, Ayana J., Dahl, Rachel A., Gibson-Corley, Katherine N., Koch, Adam T., Fu, Yang-Xin, Badovinac, Vladimir P., Laux, Douglas, Narasimhan, Balaji, Simons, Andrean L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425573/
https://ncbi.nlm.nih.gov/pubmed/30890189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0550-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak